Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Whither COVID-19 vaccines?

Nature Biotechnology convenes a group of experts to provide their insights into SARS-CoV-2 vaccines in development.

FormalPara Galit Alter

is at Harvard Medical School and the Ragon Institute, Boston, MA, USA.

FormalPara Kate Bingham

is at SV Health Managers, London, UK, and chairs the UK Vaccines Taskforce.

FormalPara Larry Corey

is at the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

FormalPara James Dahlman

is at Georgia Institute of Technology and Emory University, Atlanta, GA, USA.

FormalPara Nick Jackson

is at Coalition for Epidemic Preparedness Innovations, Shanghai, China.

FormalPara John Moore

is at Weill Cornell Medical School, New York, NY, USA.

FormalPara Rino Rappuoli

is at GlaxoSmithKline, Siena, Italy.

Questions swirl around trailblazing COVID-19 vaccines as they enter late-stage clinical testing (Tables 1 and 2), with anticipation building for an Emergency Use Authorization in the United States. How is broadening knowledge of immune responses to SARS-CoV-2 informing vaccine research? What are the pros and cons of the different vaccine modalities in discovery and clinical development? What are the key challenges associated with clinical testing, and what are their implications for safety and efficacy of immunization programs in the broader global population? And what issues related to regulatory oversight, manufacturing and distribution are likely to be important in the rollout of a COVID-19 vaccine?


  1. 1.

    Moore, J. P. & Klasse, P. J. J. Virol. 94, e01083–e20 (2020).

    CAS  Article  Google Scholar 

  2. 2.

    Pallesen, J. et al. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).

    CAS  Article  Google Scholar 

  3. 3.

    Mercado, N. B. et al. Nature (2020).

  4. 4.

    Corbett, K. S. et al. N. Engl. J. Med. (2020).

  5. 5.

    Keech, C. et al. N. Engl. J. Med. (2020).

  6. 6.

    Zhu, F. C. et al. Lancet 395, 1845–1854 (2020).

    CAS  Article  Google Scholar 

  7. 7.

    Zhu, F. C. et al. Lancet 396, 479–488 (2020).

    CAS  Article  Google Scholar 

  8. 8.

    Folegatti, P. M. et al. Lancet 396, 467–478 (2020).

    CAS  Article  Google Scholar 

  9. 9.

    Paunovska, K. et al. Sci. Adv. 6, eaba5672 (2020).

    Article  Google Scholar 

  10. 10.

    Lokugamage, M. P. et al. Adv. Mater. 32, e1904905 (2019).

    Article  Google Scholar 

  11. 11.

    Patel, S. et al. Nano Lett. 17, 5711–5718 (2017).

    CAS  Article  Google Scholar 

  12. 12.

    Jackson, N. A. C. et al. Vaccines (Basel) 5, 11 (2020).

    Google Scholar 

  13. 13.

    Corey, L., Mascola, J. R., Fauci, A. S. & Collins, F. S. Science 368, 948–950 (2020).

    CAS  Article  Google Scholar 

  14. 14.

    Xia, S. et al. J. Am. Med. Assoc. (2020).

  15. 15.

    Jackson, L. A. et al. N. Engl. J. Med. (2020).

  16. 16.

    Logunov, D. Y. et al. Lancet (2020).

  17. 17.

    Shin, M. D. et al. Nat. Nanotechnol. 15, 646–655 (2020).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Laura DeFrancesco.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. Whither COVID-19 vaccines?. Nat Biotechnol 38, 1132–1145 (2020).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing